Single-dose NEPA found non-inferior to aprepitant/granisetronJune 29, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingRelated IssuesHodgkin LymphomaNon-Hodgkin Lymphoma
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancerJune 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
New SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Chemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Inhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Biosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Severe health conditions decrease among childhood cancer survivorsJune 4, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
BLA for CAR T-cell therapy granted priority reviewMay 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
EC grants drug orphan designation for CTCLMay 25, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA grants priority review to NDA for copanlisibMay 18, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Compound could treat lymphoma, myelomaMay 17, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive Lymphomas
Intensive chemo upfront means DHL patients can skip HSCTMay 16, 2017Lymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive Lymphomas
Novel inhibitor proves ‘potent’ in hematologic malignanciesMay 9, 2017AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLALLMyelodysplastic SyndromeHodgkin Lymphoma
IV and SC rituximab produce similar results in FLMay 9, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
EMA recommends orphan status for drug for DLBCLApril 28, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
